Alzheimers Dx: An Essential Piece of the Puzzle

Article preview from Medtech Insight - February 1, 2011

Finding growth opportunities in an era of constrained spending and health care reform is not an easy task, but an increasing number of companies operating in the diagnostics space are taking aim at one underserved area they believe will be a big winner in the years ahead: Alzheimer's disease. This is a field still in its infancy and the risk of failure remains high. But as research progresses, it's becoming clear that advances in AD diagnostics could play a major role in reducing that risk.

Alzheimers Dx: An Essential Piece of the Puzzle

Article preview from Medtech Insight - February 1, 2011

Finding growth opportunities in an era of constrained spending and health care reform is not an easy task, but an increasing number of companies operating in the diagnostics space are taking aim at one underserved area they believe will be a big winner in the years ahead: Alzheimer's disease. This is a field still in its infancy and the risk of failure remains high. But as research progresses, it's becoming clear that advances in AD diagnostics could play a major role in reducing that risk.

Certainly, this is a field still in its infancy and the risk of failure remains high. But as research progresses, it's becoming clear that advances in AD diagnostics could play a major role in reducing that risk. The mechanisms underlying AD remain poorly understood, and drug companies, which have already poured millions into developing new AD therapies, have weathered a string of high-profile disappointments over the past several years—failures that have helped ignite the call for more effective diagnostic tests. In fact, there is now a fairly well-established consensus within the AD community that effective diagnostics and effective therapies will need to go hand-in-hand to truly make a significant impact on this disease.

 Continued...

To read this article in its entirety, Purchase now as a PDF and receive it immediately via email. Or get it FREE when you subscribe to Medtech Insight Newsletter.

About Medtech Insight

Medtech Insight newsletter provides insights into the technology and market developments (devices, instrumentation, biomaterials, gene therapy, tissue engineering, etc.) impacting a wide range of surgical and non-surgical clinical practices.

Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512